The unicompartmental knee arthroplasty (UKA) is often performed in older patients aged above 60 years. Results of some recent studies showed that the incidence of UKA is also increasing in relatively younger patients who less than 60-year-old.
The unicompartmental knee arthroplasty (UKA) could be a useful method for the treatment of medial compartment osteoarthritis (OA) of the knee in patients younger than 60 years of age.
Bariatric surgery when combined with dietary and exercise management resulted in signifcant weight loss, reducedd knee pain and improved functions. With this aapproach, both obesity and osteoarthritis (OA) issues can be taackled. It is a major step forward in stemming the global epidemic of these two interlinked conditions.
In both developed and developing countries, at least 2.8 million adults died due to excess body weight. Therefore, obesity is considered to be the fifth leading risk factor for deaths worldwide.
Patients with diabetic peripheral neuropathy (DPN) have worse health-related quality of life (HRQoL) compared to patients without DPN, partly mediated by functional status parameters. Effective interventions targeting functional status may be beneficial in improving HRQoL in these patients.
Diabetic patients are known to have the low quality of life (QoL). Diabetic peripheral neuropathy (DPN) accounts to be a most common complication in diabetes patients affecting almost 50% of the diabetics.
The safety and tolerability profile of baricitinib in rheumatoid arthritis (RA) up to 128 weeks, remained consistent with earlier observations, without unexpected late signals. Clinical improvements were reported during the 24-week blinded period were maintained during the open-label extension (OLE).
Rheumatoid arthritis (RA) is the most severe inflammatory disorder affecting joints severely and thus the overall quality of life of a patient.
Stepwise dose increase of febuxostat and low-dose colchicine prophylaxis effectively reduces gout flares as compaared to fixed-dose febuxostat alone. Stepwise dose increase of febuxostat may be an effective alternative to low-dose colchicine prophylaxis during the introduction of uratelowering therapy (ULT).
Gout is prevalent worldwide with consistent increase and affecting quality of life of affected patients. Gout and hyperuricemia are known to be closely associated with metabolic syndrome and renal impairment.